Filtered By:
Condition: Antiphospholipid Syndrome
Cancer: Colorectal Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Late‐onset primary antiphospholipid syndrome in the elderly: a report of seven cases
ConclusionIn this report, we report on primary APS in the elderly, to discuss its prevalence and the clinical significance of positive antiphospholipid antibodies in subjects over the age of 65 years.
Source: APLAR Journal of Rheumatology - December 20, 2014 Category: Rheumatology Authors: Yosra Cherif, Moez Jallouli, Hela Hriz, Radhouane Gouiaa, Sameh Marzouk, Mouna Snoussi, Faten Frikha, Hatem Masmoudi, Zouhir Bahloul Tags: Original Article Source Type: research
